Reading File
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/at…
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/at…
I've read the full paper. It's a 14-page review article published in Cancer Research and Treatment (2026). Since you haven't asked a specific question, here's a summary of what the paper covers:
Paper: "Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors"
Authors: Yoonjin Kwak, Jeong Mo Bae, Hye Seung Lee (Seoul National University Hospital)
Journal: Cancer Research and Treatment, 2026;58(1):1-14
DOI: 10.4143/crt.2025.1161
What the paper covers
1. Background - MMR Biology
The mismatch repair (MMR) system corrects DNA replication errors. The four key proteins are MLH1, MSH2, MSH6, and PMS2. When deficient (dMMR), errors accumulate in microsatellite sequences, producing microsatellite instability-high (MSI-H). Germline mutations cause Lynch syndrome; sporadic dMMR is mostly driven by MLH1 promoter hypermethylation.
2. Diagnostic Methods (the paper's main focus)
Four approaches are compared:
- IHC (immunohistochemistry): Minimal tissue needed (4 µm x 4 slides), fast, cost-effective, but has technical pitfalls (e.g., abnormal punctate nucleolar staining on MLH1 IHC can mimic retention).
- PCR + fragmentation analysis (Bethesda/pentaplex panels): Established standard, but requires >20% tumor purity, more tissue, and subtle shifts are hard to read in non-CRC tumors.
- NGS-based MSI calling: High concordance (~97-98% vs. PCR/IHC in CRC/EC), allows simultaneous genomic profiling; needs 10-20 slides from endoscopic biopsies.
- ctDNA liquid biopsy: Research-use mostly; sensitivity drops sharply at low tumor fractions.
3. Prevalence Across Tumor Types (Table 2)
| Tumor | Prevalence |
|---|---|
| Colorectal adenocarcinoma | 10-20% |
| Endometrial carcinoma | 16-26% |
| Gastric adenocarcinoma | 8-22% |
| Small bowel adenocarcinoma | 10-26% |
| Ovarian carcinoma | 5-15% |
| NSCLC | 0.4-0.6% |
| Breast ductal carcinoma | <0.2% |
4. Clinical Significance
- Lynch syndrome screening: dMMR triggers germline testing.
- Prognostic marker: dMMR/MSI-H is generally favorable in CRC and GC (lower stage, expansile growth, fewer distant metastases), intermediate in endometrial cancer.
- Adjuvant chemotherapy prediction: Stage II dMMR/MSI-H CRC patients derive minimal benefit from fluorouracil monotherapy. In GC, retrospective data similarly suggest MSI-H tumors do not benefit from standard adjuvant regimens.
- Immunotherapy: MSI-H/dMMR is the premier pan-tumor biomarker for immune checkpoint inhibitors. Pembrolizumab is FDA-approved as first-line for metastatic dMMR/MSI-H CRC (KEYNOTE-177). Nivolumab +/- ipilimumab approved April 2025. Neoadjuvant ICI trials in resectable dMMR CRC are showing remarkable pathological responses.
5. Immune Microenvironment
dMMR/MSI-H tumors are hypermutated, generate abundant neoantigens, and attract dense tumor-infiltrating lymphocytes (TILs). However, resistance mechanisms exist: activated Wnt/beta-catenin signaling impairs T-cell infiltration; TGFbeta-rich stroma blocks immune trafficking; compensatory upregulation of alternative checkpoints (LAG-3, TIGIT, TIM-3) can blunt PD-1 blockade efficacy. Spatial/temporal heterogeneity in MMR status is a clinically important complicating factor (~11-12% discordance between primary and metastatic sites).
Let me know if you'd like a deeper dive into any specific section, a summary for a particular audience, or anything else from this paper.
This is a shared conversation. Sign in to Orris to start your own chat.